determination of SFRP1 and SFRP2 genes promoter methylation status in patients with acute myeloblastic leukemia

Acute myeloblastic leukaemia (AML) is a heterogeneous group of hematological malignancies with great variability in the pathogenesis and clinical course. DNA methylation of CpG islands within the promoters of specific genes may play roles in tumor initiation and progression. In the present study, we studied the methylation status of SFRP1 and SFRP2 genes promoter in patients with AML and healthy individuals. Materials and methods: In peripheral blood from 43 patients afflicted with de novo AML and 25 healthy control subjects, isolated DNA was treated with sodium bisulphite and analyzed by methylation-specific polymerase chain reaction (MSP-PCR) with primers specific for methylated and unmethylated promoter sequences of the SFRP1 and SFRP2 genes.Results: the frequency of aberrant hypermethylation of SFRP1 and SFRP2 genes promoter in patients with AML determined 30.2% (13/43) and 20.9% (9/43), respectively. In addition, for all subjects in control group, methylation of SFRP1 and SFRP2 genes promoter were negative. Conclusion: The present study demonstrated that, like many solid tumors, SFRPs genes methylation also occurs in AML. Therefore the methylation of these genes may play a role in leukemogenesis initiation.

کلیدواژه ها:

AML ، SFRP ، Methylation